Physician profile
Nicholas C Lambrou
NPI 1831113950
$82,789.26
in general payments reported to CMS, 2019-2025
19 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 79% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $13K · 2021: $3,951 · 2022: $13K · 2023: $21K · 2024: $6,472 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Education: $8,000 · Travel and Lodging: $6,114 · Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,660.00 |
| Education | $8,000.00 |
| Travel and Lodging | $6,114.35 |
| Food and Beverage | $2,922.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $36,908.67 | 2019-2023 | Echelon; Endopath |
| Intuitive Surgical, INC. | $30,117.85 | 2019-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $5,480.00 | 2023-2024 | Lynparza |
| Ethicon Endo-Surgery INC. | $4,280.10 | 2019 | |
| Seagen INC. | $1,575.00 | 2022 | |
| Medical Device Business Services, INC. | $1,071.59 | 2025 | |
| Abbvie INC. | $1,020.33 | 2019-2025 | |
| Baxter Healthcare | $596.26 | 2022-2025 | Tisseel, Perclot, Floseal |
| Glaxosmithkline, LLC. | $409.37 | 2020-2025 | Zejula, Jemperli |
| Ethicon US, LLC | $391.61 | 2019-2025 | Vistaseal, Ethicon, Evarrest |
| Conmed Corporation | $383.32 | 2019-2022 | |
| Eisai INC. | $254.79 | 2020-2024 | |
| Covidien LP | $100.00 | 2019 | |
| Hologic Sales and Service, LLC | $85.91 | 2024 | Acessa Provu System |
| Pfizer INC. | $28.96 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.63 | 2024 | Keytruda |
| Corcept Therapeutics | $24.75 | 2025 | Korlym |
| Kerecis Limited | $20.40 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Myriad Genetic Laboratories, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lambrou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.